Insider Buying: Emmaus Life Sciences (NASDAQ:EMMA) CEO Buys $54,425.00 in Stock

Emmaus Life Sciences (NASDAQ:EMMA) CEO Yutaka Niihara bought 31,100 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The stock was acquired at an average price of $1.75 per share, for a total transaction of $54,425.00.

Yutaka Niihara also recently made the following trade(s):

  • On Friday, February 7th, Yutaka Niihara bought 18,800 shares of Emmaus Life Sciences stock. The stock was acquired at an average price of $1.70 per share, for a total transaction of $31,960.00.

NASDAQ EMMA opened at $1.86 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.44 and a quick ratio of 1.44. The company’s 50 day simple moving average is $2.37 and its 200 day simple moving average is $2.89. Emmaus Life Sciences has a 12 month low of $0.95 and a 12 month high of $11.76. The company has a market capitalization of $134.27 million, a P/E ratio of -0.17 and a beta of 2.91.

Emmaus Life Sciences (NASDAQ:EMMA) last released its earnings results on Tuesday, November 12th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.24. Emmaus Life Sciences had a negative net margin of 489.28% and a negative return on equity of 511.05%. The business had revenue of $6.08 million for the quarter, compared to the consensus estimate of $0.87 million. On average, analysts anticipate that Emmaus Life Sciences will post -5.57 earnings per share for the current year.

Separately, Zacks Investment Research upgraded shares of Emmaus Life Sciences from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a report on Tuesday, November 5th.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement.

Further Reading: What are economic reports?

Insider Buying and Selling by Quarter for Emmaus Life Sciences (NASDAQ:EMMA)

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with's FREE daily email newsletter.